Navigation Links
EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board

EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board -- VIENNA, Austria, September 2, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Personnel Announcements Click to view news release full screen  

EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board


VIENNA, Austria, September 2, 2010 /PRNewswire/ -- EUCODIS Bioscience, a developer and manufacturer of customized enzymes announced today the appointment of two seasoned biotechnology executives to its Advisory Board. The new appointees are Dr. David Rozzell, founder of BioCatalytics (now Codexis) and currently CEO of Solidus Biosciences, and Dr. Ulf Bethke, COO of Miltenyi Biotec. Dr. Thomas Moser, Pontis Capital, and Harald Schuerz, Wiener Wachstumsfonds, will continue to serve on the realigned Advisory Board.

With its current members, EUCODIS Bioscience's Advisory Board will focus on providing guidance and advice in the areas of strategy, market and organization, strengthening the skills and experience of EUCODIS Bioscience's management team.

"I am extremely pleased to welcome two distinguished executives of the biotechnology industry to our Advisory Board," said Thomas Fischer, CEO EUCODIS Bioscience. "Dr. Rozzell as a successful founder and entrepreneur in the enzyme industry, and Dr. Bethke with entrepreneurial mindset and his track record in biotechnology manufacturing and operations, bring to EUCODIS Bioscience a wealth of hands-on experience and operational knowledge. Having these seasoned executives on our Advisory Board will be a tremendous asset to the Company as our customer base is growing rapidly. We will continue to expand our portfolio, and are aggressively addressing new business opportunities in the pharmaceutical, bioproducts, cosmetics, and other industries."

Dr. David Rozzell is President and CEO of Solidus Biosciences, a company providing research and analytical services to the pharmaceutical and cosmetics industry, enhancing their development productivity. Prior to joining Solidus as CEO, he was the Founder and CEO of enzyme developer BioCatalytics, which he grew to a leader in its field until the company was successfully sold to Codexis in 2007. Before founding BioCatalytics, Dr. Rozzell was President and COO of Exogene.

Dr. Ulf Bethke is Chief Operating Officer of Miltenyi Biotec, one of Germany's most successful biotechnology companies. Before joining Miltenyi Biotec in 1994, he was responsible for the development and production of therapeutic monoclonal antibodies at Biotest, a German pharmaceutical company.

Dr. Thomas Moser is Managing Partner at Pontis Capital, an Austrian venture capital company. He has 10 years of experience as an investment manager, overseeing the whole investment life-cycle, from deal acquisition through active management of portfolio companies to financing and implementation of the exit strategy.

Harald Schuerz is CEO of Wiener Wachstumsfonds, an Austrian venture capital fund focusing on innovative, fast growing companies. Before joining Athena, he held executive positions at leading Austrian banks where he was responsible for venture capital investments and international financing.

About EUCODIS Bioscience

EUCODIS Bioscience provides enzymes to the chemical, health care, and other industries, and offers custom-engineering and custom-manufacturing services.

Customers use EUCODIS Bioscience' enzymes and services to make their manufacturing processes more efficient and cleaner and to introduce products with superior properties. The Company's technology of in vivo-recombination is a proven tool for the directed evolution of enzymes that perform to customers' specific requirements.

Enzymes are proteins that catalyze highly specific chemical reactions, offering a safer, cleaner, and competitive alternative to traditional chemistry. They are at the center of industrial, or "white" biotechnology, a fast growing industry segment with sales in excess of EUR100 billion.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.

For more information, please visit Company contact EUCODIS Bioscience: Thomas Fischer, MBA CEO EUCODIS Bioscience Campus Vienna Biocenter II Viehmarktgasse 2 a/ 2 OG A-1030 Vienna AUSTRIA +43-1-8900804 Media contact EUCODIS Bioscience: Frank Butschbacher Investor Relations & Communications +43-650-7844940

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience Receives EUR 2 Million Cash Injection to Enlarge Product Portfolio and Develop International Markets
2. EUCODIS Bioscience Appoints Thomas Fischer as New CEO
3. EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus
4. EUCODIS Bioscience Launches Lipase Portfolio
5. EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries
6. EUCODIS Bioscience Signs Research Agreement With Genencor
7. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
8. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
9. Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
10. Signum Biosciences Names Braham Shroot as Chief Executive Officer
11. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
Post Your Comments:
(Date:10/8/2015)... 8, 2015  Today the Wyss Institute for Biologically ... its start-up company Opsonix Inc. The announcement ... Office of Technology Development (OTD) and Opsonix Inc. ... for clinical use. --> ... million people every year in the U.S. — more ...
(Date:10/8/2015)... ... 2015 , ... Talon Innovations, a provider of Precision Machined Products ... it is one of three finalists for the Minnesota Business magazine’s Manufacturing Award in ... Talon Innovations was recognized as a nominee for this competitive award. , The ...
(Date:10/8/2015)... ... October 08, 2015 , ... Cystic ... transmembrane conductance regulator (CFTR) gene and results in dysfunction of the lungs and ... in the lungs. This mucus is very difficult to clear, blocks the airways ...
(Date:10/7/2015)... Boston Scientific (NYSE: BSX ... Boston Scientific Connected Patient Challenge , an open innovation ... remote patient monitoring to enhance patient care.  Until January ... their ideas and collaborate on solutions through Medstro,s ... Cambridge, MA where they will present ...
Breaking Biology Technology:
... and provides ... content not found elsewhere, MILFORD, Mass., Nov. 3 ... debut of an online community,designed to support the success of ... UltraPerformance,LC(R) (UPLC) System users worldwide, membership in this new online,community ...
... Neb. and GUELPH, Ontario, Nov. 3 ... an agreement to,distribute LI-COR biotechnology products in ... the local presence of Mandel Scientific skilled ... greatly enhance our ability to serve,our Canadian ...
... Albert Liou, Corporate Vice,President and General Manager, Asia-Pacific ... a leading global,biopharmaceutical services provider, will present "What ... Efficiency Savings in Running Clinical,Trials?" at the 7th ... be held November 4 - 7, 2008 at ...
Cached Biology Technology:
(Date:9/28/2015)... , September 28, 2015 The ... to reach USD 12.03 billion by 2020, growing at ... advancements such as Backside Illumination (BSI) technique to improve ... the forecast period.      (Logo: , ... the chip to reduce loss and, thus, reduce the ...
(Date:9/24/2015)... 24, 2015  EyeLock LLC, a market leader of ... winning and latest technology in Booth #602 at next ... . EyeLock,s iris authentication technology provides an ... accuracy, making it the most proven way to authenticate ... technology to deliver a fast and friendly user experience ...
(Date:9/10/2015)... , Sept. 10, 2015 Report Details ... not quite delivered upon previous expectations of revenues, consumer ... the breakthrough year in which wearables begin to achieve ... One of the main reasons is the entrance of ... only the SmartWatches market, but the overall size of ...
Breaking Biology News(10 mins):
... Care through Bio and Information Standards and Technologies, a ... standards can play in helping the United States manage ... technology investments should be made to enhance health care ... WHEN: Tuesday 25 September, 8:30 a.m. to 5:30 ...
... in French . , Vancouver, B.C. - ... Natural Resources will speak at the UBCM Pine Beetle ... under the Mountain Pine Beetle Program to help affected ... Hotel, Mackenzie Room, 900 Canada Place Way, Vancouver, B.C. ...
... counselling on diet and lifestyle offers significant benefits to ... University Technology research. Dietitian Katrina Campbell, who graduated ... 62 pre-dialysis patients at the Royal Brisbane and Women,s ... part of her thesis. Dr Campbell said depending ...
Cached Biology News:
PEG 8000 is used in the precipitation of phage, isolation of plasmid DNA and the enhancement of blunt-ended ligation reactions....
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
interferon-related developmental regulator 2...
Biology Products: